补肺定喘汤治疗支气管哮喘慢性持续期寒哮证的疗效及对患者肺功能、炎症因子水平的影响  

Efficacy of Bufei Dingchuan Decoction in treatment of cold asthma syndrome of chronic duration of bronchial asthma and its impact on the lung function and inflammatory factor levels of the patients

作　　者：李宁 毛雷刚 孟蕾 LI Ning;MAO Lei-gang;MENG Lei(Department of Respiratory and Critical Care Medicine,Fourth People's Hospital of Shaanxi Province,Xi'an 710043,Shaanxi,CHINA)

机构地区：[1]陕西省第四人民医院呼吸与危重症医学科,陕西西安710043

出　　处：《海南医学》2023年第23期3376-3379,共4页Hainan Medical Journal

基　　金：陕西省自然科学基础研究计划(编号:2020JM-394)。

摘　　要：目的探讨支气管哮喘慢性持续期寒哮证应用补肺定喘汤治疗的疗效及对患者肺功能和炎症因子水平的影响。方法选择2021年1月至2022年12月陕西省第四人民医院呼吸与危重症医学科收治的100例支气管哮喘慢性持续期寒哮证患者纳入研究,按照随机数表法将患者分为观察组和对照组各50例。对照组患者使用布地奈德福莫特罗吸入粉雾剂治疗,观察组患者在对照组治疗的基础上联合补肺定喘汤治疗,均持续治疗8周。比较两组患者治疗8周后的临床疗效,以及治疗前、治疗8周后的中医证候积分、用力呼气容积(FEV_(1))、FEV_(1)/用力肺活量(FVC)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、嗜酸粒细胞(EOS)水平和治疗期间的不良反应发生率。结果观察组患者的治疗总有效率为90.00%,明显高于对照组的72.00%,差异有统计学意义(P<0.05);治疗后,观察组患者的喘息、咳嗽、咯痰、胸闷、寒象积分分别为(1.75±0.33)分、(1.64±0.37)分、(1.66±0.36)分、(1.57±0.31)分、(1.72±0.26)分,明显低于对照组的(2.27±0.41)分、(2.08±0.43)分、(1.97±0.40)分、(1.89±0.36)分、(2.00±0.33)分,差异均有统计学意义(P<0.05);治疗后,观察组患者的FEV_(1)、FEV_(1)/FVC分别为(2.51±0.25)L、(83.35±5.60)%,明显高于对照组的(2.23±0.27)L、(78.40±5.17)%,差异均有统计学意义(P<0.05);治疗后,观察组患者的TNF-α、IL-6、EOS分别为(36.07±4.21)ng/L、(16.28±2.10)ng/L、(2.59±0.32)%,明显低于对照组的(51.24±5.82)ng/L、(21.34±2.85)ng/L、(3.17±0.48)%,差异均有统计学意义(P<0.05);两组患者治疗期间均无明显不良反应。结论补肺定喘汤治疗支气管哮喘慢性持续期寒哮证有助于改善患者的肺功能,降低血清炎症因子水平,临床应用效果显著且安全性较高。Objective To study the therapeutic effect of Bufei Dingchuan Decoction in treatment of cold asthma syndrome of chronic duration of bronchial asthma and its impact on patients'lung function and inflammatory factor levels.Methods A total of 100 patients with cold asthma syndrome chronic duration of bronchial asthma admitted to Department of Respiratory and Critical Care Medicine,Fourth People's Hospital of Shaanxi Province from January 2021 to December 2022 were selected for the study.They were randomly divided into an observation group and a control group,with 50 patients in each group.The patients in the control group were treated with budesonide and formoterol inhaled powder spray,while the patients in the observation group were treated with Bufei Dingchuan Decoction on the basis of the control group,continuously for 8 weeks.The clinical efficacy of the two groups after 8 weeks of treatment,as well as the TCM syndrome scores,forced expiratory volume(FEV_(1)),FEV_(1)/forced vital capacity(FVC),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),eosinophil(EOS)levels before and after 8 weeks of treatment,and the incidence of adverse reactions during treatment were compared between the two groups.Results The total effective rate of treatment in the observation group was 90.00%,which was significantly higher than 72.00%in the control group(P<0.05).After treatment,the scores of wheezing,coughing,phlegm,chest tightness,and cold manifestation in the observation group were(1.75±0.33)points,(1.64±0.37)points,(1.66±0.36)points,(1.57±0.31)points,and(1.72±0.26)points,which were significantly lower than(2.27±0.41)points,(2.08±0.43)points,(1.97±0.40)points,(1.89±0.36)points,(2.00±0.33)points in the control group(P<0.05).After treatment,the FEV_(1)and FEV_(1)/FVC in the observation group were(2.51±0.25)L and(83.35±5.60)%,which were significantly higher than(2.23±0.27)L and(78.40±5.17)%in the control group(P<0.05).After treatment,the TNF-α,IL-6,and EOS in the observation group(36.07±4.21)ng/L,(16.28±2.10)ng/L,

关 键 词：支气管哮喘 慢性持续期 补肺定喘汤 肺功能 炎症因子 安全性 

分 类 号：R562.25[医药卫生—呼吸系统]